MENA Metabolic Conference
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: Product News

Product News

5 PRODUCT RANDOX

Randox Labs unveils ‘All in One’ COVID-19 diagnostic analyser

, 23 December 2020/in Product News /by 3wmedia

Randox Laboratories has unveiled Randox Discovery, a revolutionary COVID-19 diagnostic analyser. The benchtop laboratory for molecular and immunoassay diagnostics is the first of its kind to combine sample preparation techniques and Biochip Technology – a patented multiplex testing platform – in one high throughput fully-automated analyser.
Randox’s patented Biochip Technology allows simultaneous detection of hundreds of targets from a single sample. The technology is capable of detecting SARS-CoV-2 and differentiating between other respiratory pathogens with similar symptoms. It can detect all known strains of coronavirus comprising SARS-CoV-2, Sarbecovirus (SARS, SARS-like & SARS-CoV-2), coronavirus 229E, coronavirus NL63, coronavirus OC43 and coronavirus HKUI.
The combination of both SARS-CoV-2 and Sarbecovirus on the panel provides added confidence in patient diagnosis and helps to reduce false positives or negatives. This ultimately enables better treatment decisions and allows for more effective isolation and de-isolation of suspected and confirmed cases.
The Discovery has a rapid turnaround time with three hours to first batch of results and results for subsequent batches every hour after.
It is fully automated enabling a single operator to run up to 3 Discovery analysers.
For more information, visit: www.randox.com/randox-discovery/
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2021/01/5_PRODUCT_RANDOX.jpg 479 1000 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Randox Labs unveils ‘All in One’ COVID-19 diagnostic analyser
1 PRODUCT AWARENESS TECHNOLOGY

Awareness Technology’s new analyser improves syphilis testing

, 23 December 2020/in Product News /by 3wmedia

Awareness Technology has recently introduced their ChemWell RPR Automated Nontreponemal analyser for the detection of syphilis. The company reports that it is the “most significant innovation to syphilis testing in the last 30 years”.
The analyser provides qualitative testing and screening for syphilis in human serum or plasma utilizing an advanced camera and software algorithm to analyse each sample.
In place of manual RPR cards, the system uses 4 standard 48-well microwell plates to analyse up to 192 samples per hour with no user intervention. High-resolution images captured by an advanced optical system are interpreted by a proven algorithm and provide an accurate and reliable negative or positive result based on the captured images.
An additional test can be run on positive samples to determine titers up to 1:2048 dilution for therapeutic monitoring. The software is included with the instrument at no additional cost and features an intuitive interface that allows for easy navigation and use.
Automated features such as fluid handling, mixing, timing, image capture, image processing, and reporting are all handled by the software.
Awareness Technology, with HQ in Palm City, Florida, US, develops, manufactures, and markets high quality in-vitro diagnostic instrumentation, and diagnostic test kits.
For more information, visit: www.awaretech.com
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2021/01/1_PRODUCT_AWARENESS_TECHNOLOGY.jpg 349 711 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Awareness Technology’s new analyser improves syphilis testing
abingdon health

Abingdon Health receives CE mark for COVID-19 antibody rapid test

, 23 December 2020/in Product News /by 3wmedia

Abingdon Health has received the CE mark for its COVID-19 antibody test, called AbC-19TM Rapid Test. The test is now approved for professional use in the UK and EU.
The test uses a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a lab.
The test will now be mass produced with roll out expected from the end of August. The company says it will produce 500,000 COVID-19 antibody tests a month from October and one million a month from January 2021.
AbC-19 Rapid Test detects IgG antibodies to the SARS-CoV-2 virus with 99.4% accuracy according to the company. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
Chris Yates, Abingdon Health CEO, said: “This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”
Abingdon Health is a UK-based medical device manufacturer. To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-Rapid Test Consortium (UK-RTC) in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per month.
The tests will also undergo ease of use trials with the general public to allow the Medical and Healthcare products Regulatory Agency to provide the necessary approvals for it to be used by the public as a home test which is expected in the coming months. These trials will be performed in conjunction with the Ulster University, using around 2000 volunteers.

  • For more information, visit: www.abingdonhealth.com

Read more

https://clinlabint.com/wp-content/uploads/sites/2/2021/01/abingdon_health.jpg 910 1286 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Abingdon Health receives CE mark for COVID-19 antibody rapid test
7 PRODUCT EKF

PrimeStore MTM novel viral transport media successfully evaluated by Public Health England for SARS-CoV-2 inactivation

, 23 December 2020/in Product News /by 3wmedia

EKF Diagnostics’ novel viral transport media PrimeStore MTM (Molecular Transport Medium) has been successfully evaluated for effective SARS-CoV-2 inactivation in a new study published by Public Health England (PHE). To work safely with live SARS-CoV-2 samples requires the use of high-containment laboratories. However, after inactivation SARS-CoV-2 material can be handled at a lower containment level, allowing more laboratories to undertake testing and thereby increasing COVID-19 testing capacity.
The PHE study evaluated numerous commercially available reagents and laboratory formulations commonly used for viral inactivation protocols by public health agencies and research laboratories globally. All the reagents tested have been used during the current COVID-19 pandemic for sample transportation and subsequent molecular processing. A total of 23 commercial reagents designed for virus inactivation, clinical sample transportation and nucleic acid extraction were assessed by PHE for their ability to inactivate SARS-CoV-2.
The study used TCID50 and blind passage techniques to test for any infectious virus still recoverable from all samples treated with the inactivation reagents. Notably, the study showed that PrimeStore MTM was the only commercially available transport reagent from the many tested from which no residual virus was detectable by either TCID50 or by the passaging of treated purified sample. This demonstrates the efficacy and safety of PrimeStore MTM in inactivating live SARS-CoV-2 samples whilst maintaining the ability to detect the target viral RNA.
In addition to this successful PHE evaluation of its effectiveness at deactivating SARS-CoV-2, PrimeStore MTM is also an FDA cleared and CE-IVD marked sample collection device. PrimeStore MTM removes the need for all cold chain logistics including sample storage; RNA and DNA are perfectly preserved for downstream molecular processing for up to four weeks at room temperature. Furthermore, because samples are rapidly inactivated, the risk of infection is eliminated, meaning samples are ready for safe testing immediately on arrival at a laboratory.
For more information, visit: www.ekfdiagnostics.com
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2021/01/7_PRODUCT_EKF.jpg 451 1000 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00PrimeStore MTM novel viral transport media successfully evaluated by Public Health England for SARS-CoV-2 inactivation
4 PRODUCT GREINER BIO ONE

Greiner Bio-One’s VeinViewer makes veins visible for venipuncture

, 23 December 2020/in Product News /by 3wmedia

Greiner Bio-One has launched their VeinViewer® which makes veins visible and helps to improve the success rate of an initial venipuncture. This significantly increases patient satisfaction and safety.
The VeinViewer uses harmless near-infrared (NIR) light which is directed towards the patient’s skin. Haemoglobin in the blood absorbs the NIR light and the surrounding tissue reflects it back to the VeinViewer device, where the data is processed into an image. Colour is added and the image is reflected on to the skin to provide a real time visualization of the blood vessels up to 10 mm below the skin.
High definition imaging technology helps provide clinicians with clear, sharp imaging which is particularly useful when vein visibility is poor.
Two VeinViewer devices are available. VeinViewer Flex is a portable device for use in emergency situations. It can also be made static by using the flexible arm to attach it to a table top or chair arm for example, which is useful when space is limited.
The VeinViewer Vision2 is a mobile imaging unit with an arm reaching up to 1.35 metres. It is attached to a trolley for easy transportation between beds or phlebotomy chairs.
For more information, visit: www.gbo.com
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2021/01/4_PRODUCT_GREINER_BIO-ONE.jpg 472 710 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Greiner Bio-One’s VeinViewer makes veins visible for venipuncture
Thermo Scientific Smart Vue 1

Thermo Fisher launches Smart-Vue Pro to ensure sample protection with remote monitoring

, 23 December 2020/in Product News /by 3wmedia

Thermo Fisher Scientific has launched the Thermo Scientific Smart-Vue Pro, a next-generation remote monitoring solution for biotechnology, pharmaceutical, clinical and academic laboratories. The device is designed to enable superior levels of sample protection, workflow efficiencies, asset/cost optimization and regulatory compliance.
With the option for an on-premise or cloud setup, the Thermo Scientific Smart-Vue Pro Remote Monitoring Solution provides real-time, continuous monitoring of critical laboratory equipment parameters and immediately notifies users about off-limit measurements that, if left unattended, could compromise sample safety and integrity. Notifications are delivered by email, text message or phone call, through a secure network, prompting corrective action.
Importantly, the Smart-Vue Pro solution delivers fully traceable data logging and secure user-level access to the complete system functionality at anytime from anywhere with Internet access, facilitating compliance with a wide range of regulatory standards, including 21CFR Part 11 and cGxP.
Operating on the LoRaWAN (Long-Range Wide Area Network) technology, the Smart-Vue Pro solution can simultaneously monitor conditions across several laboratories located on different floors or buildings. The LoRaWAN technology ensures a single receiver can cover up to 2km line of sight in urban areas, eliminating the need to invest in multiple monitoring systems. Scalability is further enhanced through the advanced modular, customizable architecture of the Smart-Vue Pro solution that supports up to four pre-calibrated Smart Digital Sensors. As a result, the system can monitor many pieces of equipment or multiple parameters within one piece of equipment at the same time. Finally, the Smart-Vue Pro solution allows for easy expansion to accommodate additional pieces of equipment without the need for costly upgrades. Overall, this improved scalability results in considerable installation, hardware and maintenance cost savings.
The Smart-Vue Pro solution features an interactive, colour touchscreen that displays data along with visual and audio alarms for at-a-glance monitoring, while enabling simplified and customizable views for an enhanced user experience.
Thermo Fisher Scientific supports the Smart-Vue Pro solution with end-to-end service and support packages to guide users through installation, validation, implementation and maintenance.
The Smart-Vue Pro solution is capable of monitoring temperatures ranging from −200°C to +150°C, relative humidity and dry contact state, with CO2 concentration and differential pressure set to be added to the system’s measurement capabilities in the near future.

  • For more information, visit: www.thermofisher.com/smartvuepro

Read more

https://clinlabint.com/wp-content/uploads/sites/2/2021/01/Thermo_Scientific_Smart-Vue__1_-scaled.jpg 2560 1462 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Thermo Fisher launches Smart-Vue Pro to ensure sample protection with remote monitoring
8 PRODUCT THERMOFISHER

New Liquid Chromatography-Mass Spectrometry Workstream offers comprehensive solution for toxicology

, 23 December 2020/in Product News /by 3wmedia

Clinical research, forensic and anti-doping toxicology laboratories facing the challenges of analysing increasing numbers of analytes in biological matrices, can now easily and rapidly optimize their liquid chromatography-mass spectrometry (LC-MS) methods for targeted screening and quantification with the new Thermo Scientific Tox Explorer Collection.
The Tox Explorer Collection offers a comprehensive LC-MS workstream for toxicology assays. It consists of proven methods enabling toxicology laboratories to achieve accurate, high-resolution data, regardless of analyte type, matrix complexities or user expertise.
The Tox Explorer Collection consists of a comprehensive library of analytes, allowing for faster identification and targeted screening assays with 1,500 compounds confirmed in a single analysis.
The Thermo Scientific Tox Explorer Collection is compromised of the following components:

    “Toxicology laboratories must ensure they carry out reliable, reproducible and sensitive analyses with a quick turnaround, using numerous instruments and software to ensure thorough sample screening,” said Brad Hart, senior director, clinical research, chromatography and mass spectrometry, Thermo Fisher Scientific.
    “The Thermo Scientific Tox Explorer Collection provides a robust, consistent, all-in-one LC-MS workstream, with an extensive library of analytes to allow for high-performance, targeted analyte screening on a daily basis.”
    To accompany the Tox Explorer Collection, Thermo Fisher Scientific offers a strong customer support network, comprising a comprehensive training and application support package. The package is coupled with a complete start-up guide that includes installation and method instructions.
    For more information, visit: www.thermofisher.com/ToxExplorer
    Read more

    https://clinlabint.com/wp-content/uploads/sites/2/2021/01/8_PRODUCT_THERMOFISHER.jpg 537 1000 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00New Liquid Chromatography-Mass Spectrometry Workstream offers comprehensive solution for toxicology

    EUROIMMUN’s test detects SARS-CoV-2 antibodies from dried blood spots

    , 23 December 2020/in Product News /by 3wmedia

    Anti-SARS-CoV-2 antibodies can be determined quickly and efficiently in capillary blood (dried blood spots) using the CE-marked test and automation systems from EUROIMMUN.
    The Blood Collection Set enables fast and convenient collection of blood from the fingertip by patients or healthcare professionals. The card containing the dried blood spots is then sent to a diagnostic lab without the need for cooling.
    For the serological analysis EUROIMMUN exclusively offers two ELISAs for detection of IgG antibodies against the spike protein S1 domain or against modified nucleocapsid protein (NCP). The S1 antigen includes the immunologically relevant receptor binding domain, which is a key target of neutralisation antibodies.
    Results obtained with the S1-based ELISA correlate well with those of neutralisation tests. NCP is the most immunodominant antigen of coronaviruses. The antigen used in the ELISA has been modified to contain only the diagnostically relevant epitopes, thus providing optimised performance.
    The S1- and NCP-based IgG ELISAs demonstrate specificities of 99.6% and 99.8% and sensitivities of 94.4% and 94.6% respectively.
    Parallel use of both ELISAs maximises the accuracy of SARS-CoV-2 antibody detection and can support determination of the SARS-CoV-2 antibody status before and after administration of future S1-based vaccines or antibody therapies.
    The ELISAs can be processed automatically with high throughput on the EUROLab- Workstation ELISA. During processing the samples are clearly identified by means of barcodes ensuring a smooth traceable workflow. The dried blood spot analysis enriches EUROIMMUN’s portfolio for COVID-19 diagnostics, which also includes IgM and IgA ELISAs, as well as the EURORealTime SARS-CoV-2 for sensitive direct virus detection by PCR.
    For more information, visit: www.coronavirus-diagnostics.com Read more

    https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002023-12-15 10:23:01EUROIMMUN’s test detects SARS-CoV-2 antibodies from dried blood spots

    Bio-Rad now offers the Platelia SARS-CoV-2 Total Ab assay

    , 23 December 2020/in Product News /by 3wmedia

    As COVID-19 continues to impact countries worldwide, accurate screening is needed to establish serological status of different populations. Bio-Rad now offers the Platelia SARS-CoV-2 Total Ab assay, for the detection of total anti-nucleocapsid antibodies (IgM, IgA, IgG) to SARS-CoV-2. In one test, the assay helps identify the immune response to coronavirus SARS-CoV-2, the virus associated with COVID-19.
    For more information, visit: https://info.bio-rad.com/cdg-sars-cov-2-ous?WT.mc_id=201012029377
    Read more

    https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Bio-Rad now offers the Platelia SARS-CoV-2 Total Ab assay
    absolute antibody 1

    Absolute Antibody offers researchers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients

    , 23 December 2020/in Product News /by 3wmedia

    Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalogue.
    The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent study to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
    Absolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
    The new neutralizing antibodies join Absolute Antibody’s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.
    Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.

    • For more information, visit: https://absoluteantibody.com/general/sars-cov-2-neutralizing-antibodies

    Read more

    https://clinlabint.com/wp-content/uploads/sites/2/2021/01/absolute_antibody__1_.jpg 494 1052 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-12-23 00:00:002020-12-23 00:00:00Absolute Antibody offers researchers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients
    Page 69 of 152«‹6768697071›»
    Bio-Rad - Preparing for a Stress-free QC Audit

    Latest issue of Clinical laboratory

    March 2026

    CLi Cover MRCH 2026
    11 March 2026

    Isomorphic Labs unveils IsoDDE, a unified AI drug design engine surpassing AlphaFold 3 in biomolecular prediction

    11 March 2026

    Androgen testing for PCOS diagnosis

    9 March 2026

    DiaSys Diagnostic Systems | ACE FS

    Digital edition
    All articles Archived issues

    Free subscription

    View more product news

    Get our e-alert

    The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

    Sign up today
    • News
      • Featured Articles
      • Product News
      • E-News
    • Magazine
      • About us
      • Archived issues
      • Free subscriptions
      • Media kit
      • Submit Press Release
    clinlab logo blackbg 1

    Prins Hendrikstraat 1
    5611HH Eindhoven
    The Netherlands
    info@clinlabint.com

    PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

    Scroll to top

    This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

    Accept settingsHide notification onlyCookie settings

    Cookie and Privacy Settings



    How we use cookies

    We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

    Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

    Essential Website Cookies

    These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

    Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

    We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

    We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

    .

    Google Analytics Cookies

    These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

    If you do not want us to track your visit to our site, you can disable this in your browser here:

    .

    Other external services

    We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

    Google Webfont Settings:

    Google Maps Settings:

    Google reCaptcha settings:

    Vimeo and Youtube videos embedding:

    .

    Privacy Beleid

    U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

    Privacy policy
    Accept settingsHide notification only

    Subscribe now!

    Become a reader.

    Free subscription